Evidence map›Paper›PMID 30770835›Full record

ArticleNature communications2019

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103

Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, Ling-Yuan Kong, Xueqing Xia, Jian Wang, Martina Ott, Jingda Xu, R Eric Davis, Longfei Huo and 5 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 2 countries.

Jun YanCenter for Brain Disorders Research, Capital Medical University, Beijing, 100069, China.
Qingnan ZhaoDepartment of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Konrad GabrusiewiczDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ling-Yuan KongDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Xueqing XiaDepartment of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jian WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Martina OttDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jingda XuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
R Eric DavisDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Longfei HuoDepartment of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ganesh RaoDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shao-Cong SunDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-7353-9400
Stephanie S WatowichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-1969-659X
Amy B HeimbergerDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. aheimber@mdanderson.org.
Shulin LiDepartment of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. sli4@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Gene-Product Auto-Targeting to Tumor VesselsR01CA120895 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, SHULIN · 2007 to 2025
$4.8M
Fgl-2 targeted therapy for reversing multi-modality immune suppressionR01CA203493 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, LI, SHULIN · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA120895NCI NIH HHS R01 CA203493
6 · The paper itself

Abstract

The original version of this Article contained errors in the author affiliations. Qingnan Zhao, Xueqing Xia, Longfei Huo and Shulin Li were incorrectly associated with Beijing Institute for Brain Disorders, 100069, Beijing, China.This has now been corrected in both the PDF and HTML versions of the Article.

Identifiers

PMID30770835
PMCPMC6377651
OpenAlexW2911354327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.